ARTICLE | Politics & Policy

Reps. show support for IPR exemptions

July 29, 2015 1:44 AM UTC

Reps. Scott Peters (D-Calif.) and Ryan Costello (R-Pa.) led a bipartisan group of 80 Representatives who submitted a (see BioCentury Extra, June 11).

The letter's authors argued an exemption from IPRs is necessary to preserve a balance between the needs for innovation and for incentivizing generic and biosimilar competition that were put in place by the Drug Price Competition and Patent Term Restoration Act (commonly known as Hatch-Waxman) and the Biologics Price Competition and Innovation Act (BPCIA). They said the IPR exemption is "crucial to maintaining the substantial R&D investments needed to develop new treatments and cures." ...